NLS PHARMACEUTICS LTD's ticker is NLSPW and the CUSIP is H57830111. A total of 7 filers reported holding NLS PHARMACEUTICS LTD in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $49,000 | +28.9% | 194,060 | 0.0% | 0.03% | +36.4% |
| Q2 2022 | $38,000 | -48.6% | 194,060 | -0.3% | 0.02% | -35.3% |
| Q1 2022 | $74,000 | -23.7% | 194,560 | 0.0% | 0.03% | -29.2% |
| Q4 2021 | $97,000 | -39.8% | 194,560 | 0.0% | 0.05% | -33.3% |
| Q3 2021 | $161,000 | -8.5% | 194,560 | 0.0% | 0.07% | +10.8% |
| Q2 2021 | $176,000 | -4.9% | 194,560 | 0.0% | 0.06% | -27.8% |
| Q1 2021 | $185,000 | – | 194,560 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AIGH Capital Management LLC | 827,921 | $2,069,000 | 0.44% |
| Worth Venture Partners, LLC | 194,560 | $161,000 | 0.07% |
| ARMISTICE CAPITAL, LLC | 500,000 | $413,000 | 0.01% |
| Warberg Asset Management LLC | 35,480 | $29,000 | 0.01% |
| Hudson Bay Capital Management LP | 200,000 | $154,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| UBS Group AG | 2,635 | $2,000 | 0.00% |
| Bank Julius Baer & Co. Ltd, Zurich | 7,370 | $6,000 | 0.00% |